Abstract
The genetic and molecular basis of sickle cell disease (SCD) has long since been characterized but the pathophysiological basis is not entirely defined. How a red cell hemolytic disorder initiates inflammation, endothelial dysfunction, coagulation activation and eventually leads to vascular thrombosis, is yet to be elucidated. Recent evidence has demonstrated a high frequency of unprovoked/recurrent venous thromboembolism (VTE) in SCD, with an increased risk of mortality among patients with a history of VTE. Here, we thoroughly review the molecular basis for the prothrombotic state in SCD, specifically highlighting emerging evidence for activation of overlapping inflammation and coagulation pathways, that predispose to venous thromboembolism. We share perspectives in managing venous thrombosis in SCD, highlighting innovative therapies with the potential to influence the clinical course of disease and reduce thrombotic risk, while maintaining an acceptable safety profile.
Introduction
Renewed interest in sickle cell disease (SCD) as a significant global health problem by academia, industry and policy makers is leading the resurgence of efforts to treat or cure patients with this disease. Drug development has recently led to US Food and Drug Administration (FDA) approval of three new agents (L-glutamine, crizanlizumab, voxelotor) adding much needed diversity to the hitherto lone disease-modifying therapy, hydroxyurea (HU).1 Moreover, advanced phase clinical trials of molecules targeting diverse disease mechanisms, if efficacious, could ameliorate the protean manifestations of SCD. In addition, curing SCD either through stem cell transplantation or gene therapy has become a reality for a small number of patients.2 Given the October 2019 joint National Institutes of Health (NIH)-Bill and Melinda Gates Foundation funding declaration, inclusion of patients from high disease burden resource-scarce settings in such trials of novel curative therapies seems plausible.3 Prospects appear particularly promising for SCD patients in resource-scarce settings worldwide, where the need is greatest.
Despite these advances, many patients with SCD continue to experience severe complications, and understanding the pathophysiology of “downstream” events remains important for the development of therapies to target specific complications. One of these phenomena is the sickle prothrombotic state that is largely believed to be responsible for both arterial and venous thrombosis in SCD. In its most devastating form, thrombosis occurs in arteries leading to overt stroke and silent cerebral infarction in SCD patients as early as childhood.4,5 In adulthood, SCD patients develop deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively termed venous thromboembolism (VTE).6-8 Thrombotic vasculopathy in SCD is accompanied by significant organ dysfunction, morbidity from diminished quality of life, and mortality.6,7 Yet, how the complex pathobiology initiated by sickle RBC-mediated endothelial inflammation/dysfunction and coagulation activation leads to vessel injury, leakage, and vascular thrombosis remains to be clarified. At the mechanistic level, there is a scientific gap in our understanding of coagulation-mediated pathologies of SCD, a fact noted in the National Heart, Lung, and Blood Institute (NHLBI) evidence-based guidelines,9 which makes this an active area of research. Therefore, gaining insight into the pathophysiological basis for the prothrombotic state in patients with SCD and how one might attenuate thrombotic risk is of the utmost importance. Studies of vascular pathobiology using in vitro and animal models of SCD have identified both insightful and discrepant findings, when compared with human SCD, as noted in the accompanying review in this issue of the Journal by Conran and De Paula.10 Here we examine the molecular basis for the prothrombotic state and establish the scientific rationale to target dysregulated coagulation pathways in patients with SCD. For a more comprehensive overview of arterial thrombosis and/or SCD management, the reader is referred to recent publications in the literature.1,11-13
Sickle cell disease: an acquired hypercoagulable state
The underlying mechanism(s) for the prothrombotic tendency in SCD has been the subject of speculation for many decades.14,15 Several clinical observations suggest that the presence of sickle hemoglobin (HbS) is either directly or indirectly associated with the development of thrombotic complications in SCD. The early age of onset of arterial complications such as stroke and silent cerebral infarction in children with hemoglobin SS disease, in particular, is a clear example of the thrombotic potential associated with hemoglobin S. Furthermore, in adults, a wide range of sickling hemoglobinopathies have been associated with the development of VTE, from hemoglobin SS to compound heterozygous states to sickle cell trait (SCT).
Numerous epidemiological studies of VTE in SCD have verified an increased risk of this complication (Table 1). A retrospective analysis of the Cooperative Study of SCD demonstrated a 11.3% cumulative incidence of VTE by the age of 40,16 and a similarly high incidence was found in a large California discharge database.7 These estimates are particularly striking when compared to population studies of patients with thrombophilia, as the incidence rates of VTE observed in SCD are similar to those found in families with high-risk thrombophilia such as protein C and S deficiency.16 In addition, after controlling for confounding factors such as hospitalization, studies have found that VTE rates are high even among SCD with a lower number of hospitalizations,7 and that VTE prevalence in pregnant women with SCD increases approximately 5-fold compared to non-SCD pregnant women.17,18 Furthermore, the recurrence rate of VTE in SCD has also been noted to be exceedingly high (>35% at 5 years),8,16 another indication of the persistent thrombogenic potential in SCD.
Further confirmation of the relationship between the presence of HbS and a prothrombotic state are observations noted in healthy individuals with SCT. In two large population-based studies, VTE risk in individuals with SCT was almost 2-fold higher than ethnic-matched counterparts, despite the absence of either clinical sickling symptoms or HbS percentages encountered in patients with SCD (Table 1).19,20 As with the known pathophysiology of SCD complications, the presence of HbS alone is unlikely to be the sole contributor to thrombotic risk. Additional mechanisms, described further below, are likely to contribute to the acquired prothrombotic state in SCD.
Clinical and genetic risk factors for the prothrombotic state
Clinical and biological factors provide insight into why a genetic disorder primarily involving red cells sets off a cascade of events leading to an acquired prothrombotic state. Risk factors for VTE in SCD include increased disease severity (as measured by averaging ≥3 hospital admissions a year for VOC), exposure to erythropoiesis stimulating agents or blood transfusion, insertion of central venous catheters (CVC), surgical splenectomy, and hospitalization.21-24 As mentioned above, not only are SCD patients at a high risk for developing early onset VTE, but their risk for VTE recurrence after an index VTE has been noted to be high. Clinical risk factors for VTE recurrence include averaging >3 hospital admissions a year, lower extremity DVT as the index event, and a prior history of pneumonia/acute chest syndrome (ACS).8,23 Incomplete adherence to anticoagulation is also likely to contribute to higher recurrence rates, though this has not been formally evaluated. In a single center retrospective study, use of direct oral anticoagulants (DOAC) was associated with lower recurrence rate.23
Genotype may also modify thrombotic risk in SCD. Certainly, children with HbSS/Sβ0 are at highest risk for arterial thrombosis such as stroke.5,23 In terms of VTE, the influence of genotype has not been fully elucidated, with some studies demonstrating an increased risk of VTE among sickle variant syndromes and others showing the highest risk among HbSS/Sβ0.6,16 The influence of co-inheritance of either α-thalassemia or gene modifiers regulating human fetal hemoglobin expression25-27 or both, has not been studied for VTE but may attenuate stroke risk.5
The influence of heritable thrombophilia mutations on VTE risk in SCD remains to be completely determined. Genetic variants, factor V Leiden and prothrombin FII G20210A in particular explain up to 50% of unprovoked VTE among Caucasians.28 Notably, VTE risk is 5-fold higher in individuals reporting African descent compared with those reporting Asian descent, whereas white individuals have only an intermediate-level risk.29 However, factor V Leiden and prothrombin FII G20210A have low allele frequencies among individuals reporting African descent and are not associated with venous thrombosis in SCD.30,31 Thus, other heritable or acquired thrombophilia- associated mutations could explain thrombotic risk in SCD. One recent study identified two known thrombomodulin gene variants (THBD rs2567617 and rs1998081) that were associated with arterial and venous thrombosis in SCD patients.23 A recent genome-wide association study conducted among African Americans in the general population identified three novel intronic gene variations (LEMD3, LY86, LOC100130298) associated with higher odds of developing VTE.32 LEMD3 encodes for a nuclear membrane protein that interacts with transforming growth factor (TGF)-β to downregulate the activation of TGF-β target genes33,34 and LY86 encodes for MD-1, which regulates expression of a cell surface protein homologous to toll-like receptor (TLR) 4.35,36 Given the involvement of the innate immune system in both VTE37 and the vascular pathobiology of SCD,10 genetic dysregulation of these pathways in SCD patients could influence thrombophilia. Acquired mutations also influence thrombotic risk; JAK2V617F the most frequent age-induced clonal hematopoietic mutation is associated with increased venous thrombotic events.38 Future studies may clarify the role of these heritable or acquired mutations.
Thrombo-inflammatory processes in sickle cell disease that alter hemostatic balance
A triad of thrombosis risk factors first described by Virchow that includes increased blood coagulability, altered blood flow (stasis) and endothelial dysfunction, are all evident in SCD.39 The endothelium, a critical regulator of thrombo-inflammatory processes maintains vascular health by exerting anti-coagulant, anti-inflammatory, and anti-platelet actions. The sickle proinflammatory state leads to endothelial dysfunction, thereby shifting the hemostatic balance towards a prothrombotic state (Figure 1). Accumulated evidence suggests that SCD is a thrombo- inflammatory disorder as reflected by alterations in components of coagulation and inflammatory pathways. 40-43 This is most clearly demonstrated in the acute exaggerated thrombo-inflammatory response that accompanies ischemia-reperfusion (IR) injury in SCD patients.44 Endothelial inflammation leads to surface expression of adhesion molecules (P-selectin and E-selectin) and release of prothrombotic granule contents (von Willebrand factor and FVIII), both effects enhancing leukocyte/platelet adhesion (Figure 2). Repeated VOC episodes amongst other pathophysiology leads to hemolysis and subsequent release of cell-free heme/hemoglobin. By activating converging inflammatory pathways, such as TLR signaling,45 NETosis/neutrophil extracellular trap (NET) formation46 and priming the inflammasome,47 cell-free heme amplifies inflammation (Figures 1 and 2).48 Inflammation, shear stress and hypoxia, which are common phenomena in VOC, under experimental conditions can induce abnormal endothelial TF gene and protein expression.49-51 SCD patients demonstrate abnormally elevated levels of intravascular TF that is believed to trigger activation of coagulation and pathological thrombosis.52-55 Critically, intravascular TF binding with factor VIIa activates the extrinsic pathway of coagulation by converting coagulation factor X to Xa and generating thrombin (Figure 3), which, unchecked, leads to vascular fibrin deposition. From this perspective, defining the molecular mechanisms regulating these thrombo-inflammatory processes in SCD and identifying interventions to counter vascular thrombosis is of major relevance.
Cellular components of blood that facilitate thromboinflammation
Sickle red cells
That red cells in SCD are likely to be involved in thrombus formation is supported by the relationship between hematocrit and VTE,24 possibly resulting from alterations in viscosity, adhesive cellular interactions, and microvascular stasis.56,57 Studies of sickle red cells have identified numerous receptors and ligands that mediate adhesive interactions with the vessel wall, implicating their role in post capillary venule occlusion (Figure 2).58,59 Elevated numbers of phosphatidylserine (PS) positive sickle red cell and red cell derived extracellular vesicles (EV) are observed in SCD patients, which correlate with markers of thrombin generation.55,60,61 In non-SCD models, venous thrombus size is impacted by localization of red cells within blood clots, which in turn is affected by fibrin network density and fibrin α-chain crosslinking activity.62,63 Recent studies in SCD mice have shown higher amounts of fibrin deposition and red cell entrapment within the developing venous thrombus64 that are likely to impact thrombus structure and stability. These findings imply that venous clots in SCD patients and individuals with SCT are more friable and prone to embolization, possibly explaining why individuals with sickling hemoglobinopathies appear to have a higher risk of PE compared to DVT.6,7,19,65 However, in situ pulmonary thrombosis in SCD patients66 suggests heterogenous mechanisms, that may include abnormal pulmonary vascular endothelial TF expression.67
Platelets
Due to the physiological role platelets play in primary hemostasis, platelet activation probably contributes to thrombosis in SCD. For example, activated platelets in SCD can recruit leukocytes to sites of inflammation through surface P-selectin, and release prothrombotic granule contents. Besides, activated platelets form homotypic and heterotypic cell-aggregates, and platelet-neutrophil aggregates contribute to pulmonary arteriolar micro emboli.68-71 In recent studies, both murine models and SCD patients have consistently demonstrated activation of the platelet NLRP3 inflammasome, suggesting an autocrine feedback loop for IL-1β driven priming of innate immune and vascular endothelial cells.68,72 Moreover, soluble CD40L and thrombospondin-1, two platelet-derived molecules are reportedly elevated in SCD patients with a history of ACS,73,74which, in the light of dense platelet-rich thrombi found on autopsy in the pulmonary vasculature of over half of ACS patients,75 provides evidence for platelet-mediated thrombosis.
Leukocytes
Innate immune cells mediate SCD pathophysiology, as recently reviewed in this Journal.76 Amongst these, monocytes and neutrophils facilitate thrombotic vasculopathy by directly inducing endothelial injury and activating coagulation. Neutrophils undergo NETosis, a neutrophil defense mechanism that involves the release of NET and initiates venous thrombosis.77 In vitro studies suggest that actually cell-free DNA (cfDNA) and histones, rather than intact NET, activate coagulation,78 and while SCD patients have elevated plasma levels of cfDNA, histones and NET,79,80 no direct evidence links them with VTE development. Neutrophil-endothelial and neutrophil-platelet cross-talk, mediated via P-selectin-PSGL1 interactions are key aspects of SCD pathobiology, as evidenced by the clinical efficacy of the anti-P-selectin antibody crizanlizumab (Figure 2).81Monocytes regulate important aspects of blood coagulation, innate immune response, reticuloendothelial function, and phagocytosis. Circulating TF+ monocytes and TF+ monocyte EV form the major fraction of measurable blood borne TF and thus contribute meaningfully to coagulation abnormalities observed in SCD patients.54,55 Monocyte activation by heme and placental growth factor (PLGF) released from sickle red cells can stimulate the production of proinflammatory cytokines and chemokines (e.g., IL-1β, TNF-α, MCP-1 and MIP- 1β),45,82,83 that in turn are capable of inducing TF gene expression.84 Lastly, frequent VOC in SCD could reduce the number of patrolling monocytes (CD14lowCD16+) responsible for restoration of endothelial function85 thereby augmenting endothelial injury and dysfunction.
Molecular components in blood facilitating thromboinflammation
Blood borne tissue factor
As described above, intravascular TF expression in the setting of SCD-related endothelial damage is likely a major contributor to the hypercoagulable state of SCD; however, the role of “blood borne” TF in SCD-related thrombosis is largely unknown.86-89 Studies have shown that SCD patients have elevated blood borne TF procoagulant activity.52-55,90 Specifically, TF+ EV, which are derived from monocytes and endothelial cells, have been found to be elevated in SCD patients during acute VOC.54 Although, frequent VOC in SCD has been associated with an increased risk of VTE,7 no studies have evaluated whether cell-surface TF expression or TF+ EV play a direct role in initiating venous thrombosis.
Several other regulatory mechanisms could modify VTE risk in SCD, as not all SCD patients with elevated levels of blood borne TF experience pathological thrombosis. For example, inactivation of blood borne TF by tissue factor pathway inhibitor (TFPI) probably protects against pathological thrombosis,91 but TFPI antigen levels in SCD patients are found to be normal.53 Besides, the procoagulant activity of TF is under post-translational regulatory control; these mechanisms are beyond the scope of this discussion but are reviewed elsewhere.92 Regulation of TF procoagulant activity could limit overt clinical thrombosis in SCD but does not appear sufficient to inhibit TF and thrombin-mediated inflammatory vasculopathy.41,93
Thrombin generation
Activation of coagulation either through the TF or contact factor pathways leads to generation of thrombin. Thrombin, one of the most potent biological proinflammatory molecules, activates both cellular and plasmatic components of blood. These actions primarily include cleavage of factors comprising the plasma coagulation, complement and fibrinolytic cascades. In addition to converting soluble fibrinogen to insoluble fibrin, thrombin activates complement, innate immune cells, the endothelium and platelets, which in SCD mediates vascular thrombosis and vessel wall remodeling (Figure 3).41,93 Moreover, overwhelming evidence for thrombin-mediated vasculopathy is derived from elegant studies in sickle mouse models.40,41,94
In the aftermath of the initial thrombin burst generated by the TF-VIIa complex, a continuous supply of thrombin generation is required for pathological thrombosis. Thrombin generation is sustained in SCD patients even during the steady state, as demonstrated by the observation of elevated plasma levels of thrombin-anti thrombin complexes, D-dimers, and prothrombin fragment 1.295-97 and elevated in vitro thrombin generation potential.98 The contact pathway (plasma kallikrein-kinin system) is also implicated in sustaining thrombin generation in SCD patients,99,100 and endogenous activators of the contact pathway, e.g., PS on the surface of red cells and EV,99,100 polyphosphates (polyP) released by platelets, and nucleic acids (NET or cfDNA)80 are elevated in both SCD patients and those with SCT.101 Thus, both TF and the contact pathway activation contribute to thrombin generation in SCD patients.15
Canonical pathways critical to thrombosis pathophysiology
Several concurrent inflammatory processes increase thrombotic risk in SCD. In the absence of pathogenic organisms, cell death and release of damage-associated molecular patterns (DAMP) trigger a vascular response termed “sterile inflammation”. In SCD, DAMP prime the innate immune system through converging inflammatory pathways, such as TLR signaling, NETosis (see above) and activation of the inflammasome.43 Murine studies that delineate how prototypic DAMP molecules (e.g., cell-free hemoglobin and high-mobility group box 1 [HMGB1]) play a critical role in VTE pathophysiology offer major insight into the occurrence of thrombosis in SCD.45,80,102-105 As noted above, cell-free hemoglobin is proinflammatory and prothrombotic due to nitric oxide (NO) consumption, 106 induction of endothelial surface TF107 and TLR4- induced monocyte priming.45 Similarly, disulfide HMGB1, derived from platelets, prime the leukocyte inflammasome and induce NET, facilitating VTE development in a murine model.102 Plasma HMGB1 levels are elevated in patients with SCD,72,103 but their contribution to NET formation and VTE pathophysiology in SCD is uncertain. Murine models of intravascular hemolysis demonstrate a co-operative role for complement activation and P-selectin in mediating thrombotic injury of hepatic and renal vascular endothelium, and provide insight into how sickle hemolysis might mediate organ injury.104,108 Taken together with the findings that HU attenuates complement activation in SCD patients109 and the efficacy of P-selectin blockade in preventing VOC,81 it is apparent that modulating these pathways may offset microvascular thrombosis. Advancing our understanding of these complex interactions between dysregulated inflammation and coagulation processes in SCD might offer additional insights and identify new therapeutic targets to limit thrombosis, particularly VTE.
Thromboinflammation, vascular injury and vasculopathy
In addition to pathological thrombosis occurring as a result of the TF/VIIa complex (as described above), cell surface TF expression leads to inflammation. TF-mediated inflammation occurs either via the effects of downstream coagulation proteases (see above) on other vascular endothelial and blood cells94 or intracellularly, via its cytoplasmic tail.88 Thrombin’s subsequent interaction with endothelial cell surface protease activating receptors (PAR) accentuates vascular endothelial inflammation in SCD.110 Continued activation of coagulation, initially triggered by TF, likely occurs via EV and PS positive red cells in circulating blood, that by virtue of their surface PS content support the assembly of tenase and prothrombinase complexes111 (Figures 1 and 3). Moreover, in addition to procoagulant effects exerted by surface TF and PS, EV display membrane surface antigens, e.g., P-selectin, that engage with ligands to enhance production of TF+ EV112,113 and reactive oxygen species (ROS).105 Splenic hypofunction and diminished reticuloendothelial clearance in SCD lead to accumulation of prothrombotic mediators, i.e., PS+ red cells, red cell derived EV and leukocyte/endothelial derived TF+ EV. In venous vascular beds prone to stasis and hypoxia, accumulation of procoagulant factors may overwhelm anticoagulant defenses and lead to pathological thrombosis.
A likely sequence of events may include the following: (i) sluggish cell transit through the post capillary venules which may increase “delay time”114 augmenting the fraction of polymerized HbS; and (ii) formation of hetero and homotypic cellular aggregates that, coupled with increased endothelial cell adherence promote stasis, lead to further red cell sickling, vaso-occlusion, and ischemic crisis. These sickling cycles promote repeated vascular injury, vasomotor dysfunction, chronic inflammation and vasculopathy in patients with SCD.115,116 Moreover, the cumulative effects of stasis, altered rheology, vascular fibrin deposition and chronic inflammation ultimately leads to chronic vasculopathy47 and characterizes the multiorgan failure observed in SCD patients.117 Vasculopathy in patients experiencing DVT is reflected by the onset of post-thrombotic syndrome, valvular venous insufficiency or leg ulceration and, in patients experiencing PE, by the onset of chronic thromboembolic pulmonary hypertension (CTEPH).118 The sickle prothrombotic state and resulting VTE, therefore, results in considerable cardiopulmonary morbidity and mortality.
Managing venous thrombosis in sickle cell disease
Because prospective trials of anticoagulation in VTE have not, to our knowledge, included subjects with SCD, recommendations on VTE management in SCD patients generally rely on clinical guidelines developed for the general population.119 It should be noted that, while clinical probability scores and laboratory biomarkers help determine the pretest probability of VTE in the general population, 120 there is no evidence to support this approach in SCD patients. In addition, the lack of prospective primary prevention and/or management studies of VTE in either pregnant women with SCD or high-risk SCD patients leads to over-reliance on data from prospective studies of VTE in individuals with inherited prothrombotic states.39
Patients with SCD who are suspected of having VTE should undergo compression ultrasound Dopplers for DVT and multidetector computerized tomographic pulmonary angiography and/or radionuclide scanning (ventilation- perfusion [V/Q] scanning) for PE.39 Subsequent management of confirmed VTE occurs in two phases: (i) “active treatment” consisting of therapeutic dose anticoagulation for three months to suppress the acute episode of thrombosis; and (ii) “secondary prevention” consisting of therapeutic or prophylactic dose anticoagulation for an indefinite duration to prevent new VTE episodes unrelated to the index event.39
According to ACCP guidelines, in patients with a low risk of bleeding, a risk of recurrent VTE of >13% in the first year results in a strong recommendation and a risk of 8-13% in the first year results in a weak recommendation for indefinite anticoagulation therapy.119 Prior cohort studies have suggested that the VTE recurrence rate in SCD ranges from approximately 25-40%,8,16 although anticoagulation adherence data are generally lacking in these studies. Nonetheless, the high VTE recurrence rate in SCD patients appears to justify indefinite anticoagulation as an efficacious secondary prevention strategy, especially in patients with unprovoked or recurrent provoked thrombosis. 121
Even SCD patients with less severe disease have high VTE recurrence rates (18% at 5 years) with no difference according to whether the incident event occurred within or >90 days after hospitalization,6,8 suggesting that most patients are likely to benefit from secondary prevention. However, caution may be warranted, as clinical and plasma biomarkers that reliably predict VTE recurrence in SCD patients have not been identified to guide decision making in this subgroup, unlike in the general population with unprovoked VTE.120 When considering indefinite anticoagulation therapy, the perceived risk/benefit ratio influences both patients and physicians alike. Population-based studies reveal a non-linear bleeding risk associated with indefinite anticoagulation, which increases with age, disease comorbidity, polypharmacy, and renal insufficiency.28 In addition, a high incidence of bleeding, particularly gastrointestinal bleeding, has been noted in SCD patients exposed to anticoagulation.122 Thus, evaluating common risk factors, such as prior bleeding episodes, severe anemia, thrombocytopenia, renal and hepatic failure, use of antiplatelet and NSAID, can inform decisions about both anticoagulant choice and duration of therapy in SCD. Moreover, assessing for central nervous system (CNS) vasculopathy (Moya Moya disease and aneurysmal dilatation of cranial vessels), which can increase the risk of intracranial hemorrhage even in the absence of anticoagulation, is important.
The primary goal of anticoagulation is to limit and resolve thrombosis with minimal perturbation of hemostasis. Among all the available anticoagulants, the DOAC come closest to achieving this goal, although the risk of bleeding is not completely eliminated. For instance, in patients with VTE and no active cancer, a meta-analysis revealed that DOAC were at least as effective as warfarin but reduced the risk of major bleeding only by 40% and did not completely eliminate it.123 Prospective evidence from a meta-analysis of two randomized trials of DOAC in cancer-associated VTE reported 6-month outcomes of improved efficacy with DOAC compared to dalteparin (relative risk [RR] of recurrent VTE: 0.65; 95% confidence interval [CI]: 0.42-1.01), but the risk of bleeding was greatly increased (major bleeding RR: 1.74; 95%CI: 1.05-2.88 and non-major bleeding RR: 2.31; 95%CI: 0.85-6.28).124 In patients with SCD-associated VTE anticoagulation associated bleeding is particularly evident. Retrospective analysis of anticoagulation for SCD-associated VTE reveals a cumulative bleeding incidence of 4.9% (95%CI: 3.5-6.4%) at 6 months and 7.9% (95%CI: 6.2-9.8%) at 1 year.8 In patients with severe SCD, the bleeding risk was greatest (HR: 1.61; 95%CI: 1.11-2.35).8 Similarly, smaller retrospective studies indicate that all anticoagulants have an increased bleeding risk, with DOAC having the least risk.23,125,126 In spite of these advantages, the exact role for DOAC in the management of VTE in SCD patients is not clear.
Perspectives
Dysregulation of inflammatory and coagulation pathways, both during the steady state and during VOC, are an important hallmark of the sickle prothrombotic state. They appear to be directly associated with the development of thrombotic complications, such as VTE, which is known to increase SCD morbidity and mortality. Given the important role of coagulation in SCD, it is valid to expect that sickle specific therapies seeking to reduce inflammation and coagulation biomarkers would have an effect on lowering thrombosis incidence. Although some sickle specific therapies (HU and transfusion) are associated with reduced arterial thrombosis risk,13 surprisingly few studies have evaluated the effect of these therapies on venous thrombosis. HU use was associated with reduced biochemical indicators of coagulation activation in SCD patients127 when compared with non-users, and led to lowered cfDNA levels.79 In myeloproliferative neoplasms, prospective studies of HU have shown a reduction in thrombosis biomarkers and thrombosis risk,128 but the lack of similar studies in SCD makes this area a research priority. For instance, targeting P-selectin can diminish heterotypic cellular adhesive interactions (see above) and may prevent vascular endothelial cell activation and injury. Considering its mild adverse event profile, 81,129 crizanlizumab could possibly lower the incidence of thrombosis in SCD without compromising hemostasis.
Given the diverse pathophysiological processes involved in SCD, it is important to narrow down key thrombo-inflammatory pathways involved in VTE pathobiology and design interventions specifically targeting venous thrombosis. From this viewpoint, several trials evaluating the effects on anticoagulants on modulating the vascular pathobiology of SCD are either ongoing or completed (Table 2). However, concerns regarding study design and implementation limit the interpretability of several of these studies, emphasizing the challenges faced by clinical investigation in this field. Nonetheless, implementation of a double-blinded, randomized, placebo controlled trial of prasugrel in children with SCD130 demonstrates feasibility of rigorous scientific experimentation in this population, and provides hope for future efficacy studies of thrombosis endpoints.
Because traditional anticoagulation for VTE in the general population and in SCD patients is associated with increased bleeding, the development of safer anticoagulant treatments is of considerable importance. Besides, as indicated above, even DOAC fail to suppress TF-mediated inflammation or prevent chronic organ dysfunction in SCD,41 suggesting the need for novel therapies. Targeting coagulation factors involved in SCD pathobiology (specifically TF and contact pathway components, e.g., FXII and FXI) would appear to have a lowered bleeding risk, especially those that are not involved in physiological hemostasis, i.e., contact pathway factors.131 For example, anti-XI therapy is both safe and efficacious for VTE prevention in the general population132 but this approach is untested in SCD. Moreover, as TF plays an important role in physiological hemostasis, therapeutic agents that inhibit TF-mediated inflammation while sparing TF-procoagulant activity are worth developing. Finally, drugs that target post-translational mechanisms regulating TF procoagulant activity, e.g., annexins or thiol-disulfide exchange inhibitors,92 could prevent pathological thrombosis.
Selecting drugs with a demonstrably lower propensity for bleeding is another approach to maximize anti-thrombotic efficacy in SCD without altering hemostasis. Aspirin, with its low bleeding risk, antithrombotic efficacy for secondary prevention of VTE,133 and proven safety in SCD may have an important thromboprophylaxis role. Statins reduce markers of hypercoagulability in subjects with unprovoked VTE after cessation of anticoagulation treatment,134 reduce abnormal pulmonary vascular TF expression in SCD mice,67 and are generally safe in SCD patients,135 providing a rationale for their further investigation in VTE thromboprophylaxis. Canakinumab, an IL-1β******antagonist, is associated with a reduction in all-cause mortality from atherothrombotic coronary artery disease, largely via its anti-inflammatory effects.136 Elevated IL-1β******levels and dysregulated inflammatory pathways in SCD patients, along with the relative safety of canakinumab in children with SCD (clinicaltrials.gov identifier: NCT02961218), provide a compelling rationale for testing this agent. Evaluating these therapies in the setting of controlled clinical trials would demonstrate their potential role for secondary VTE prevention in SCD.
In spite of the advances in treatment and prevention, venous thrombosis profoundly impacts chronic organ dysfunction and mortality in patients with SCD. Major scientific advances have furthered our understanding of the vascular pathobiology of SCD and led to the development of novel therapeutic agents optimal for clinical investigation. Conducting effective preventative and treatment studies to reduce VTE in SCD and establishing the scientific evidence base to guide appropriate management has therefore become a research priority. The design of these studies should include endpoints that account for simultaneous effects on anti-thrombotic efficacy and harm due to bleeding.
Footnotes
- Received April 6, 2020
- Accepted July 22, 2020
Correspondence
References
- Tisdale JF, Thein SL, Eaton WA. Treating sickle cell anemia. Science. 2020; 367(6483):1198-1199. https://doi.org/10.1126/science.aba3827PubMedPubMed CentralGoogle Scholar
- Benz EJ, Mondoro TH, Gibbons GH. Accelerating the science of SCD therapies-is a cure possible?. JAMA. 2019. https://doi.org/10.1001/jama.2019.11419PubMedGoogle Scholar
- Collins FS. Curing HIV and sickle cell falls short if the most vulnerable populations are left out. Fortune. 2020. Google Scholar
- Adams RJ, McKie VC, Hsu L. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998; 339(1):5-11. https://doi.org/10.1056/NEJM199807023390102PubMedGoogle Scholar
- Ohene-Frempong K, Weiner SJ, Sleeper LA. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998; 91(1):288-294. Google Scholar
- Naik RP, Streiff MB, Haywood C Jr. Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. J Thromb Haemost. 2014; 12(12):2010-2016. https://doi.org/10.1111/jth.12744PubMedPubMed CentralGoogle Scholar
- Brunson A, Lei A, Rosenberg AS. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol. 2017; 178(2):319-326. https://doi.org/10.1111/bjh.14655PubMedGoogle Scholar
- Brunson A, Keegan T, Mahajan A. High incidence of venous thromboembolism recurrence in patients with sickle cell disease. Am J Hematol. 2019; 94(8):862-870. https://doi.org/10.1002/ajh.25508PubMedPubMed CentralGoogle Scholar
- Yawn BP, Buchanan GR, Afenyi-Annan AN. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312(10):1033-1048. https://doi.org/10.1001/jama.2014.10517PubMedGoogle Scholar
- Conran N, De Paula EV. Thromboinflammatory mechanisms in sickle cell disease-challenging the hemostatic balance. Haematologica. 2020; 105(10):2380-2390. https://doi.org/10.3324/haematol.2019.239343PubMedPubMed CentralGoogle Scholar
- Telen MJ, Malik P, Vercellotti GM. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nat Rev Drug Discov. 2019; 18(2):139-158. https://doi.org/10.1038/s41573-018-0003-2PubMedPubMed CentralGoogle Scholar
- Matte A, Cappellini MD, Iolascon A. Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?. Expert Opin Investig Drugs. 2020; 29(1):23-31. https://doi.org/10.1080/13543784.2020.1703947PubMedGoogle Scholar
- Kassim AA, Galadanci NA, Pruthi S. How I treat and manage strokes in sickle cell disease. Blood. 2015; 125(22):3401-3410. https://doi.org/10.1182/blood-2014-09-551564PubMedPubMed CentralGoogle Scholar
- Wun T, Brunson A. Sickle cell disease: an inherited thrombophilia. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):640-647. https://doi.org/10.1182/asheducation-2016.1.640PubMedPubMed CentralGoogle Scholar
- Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 2016; 30(4):245-256. https://doi.org/10.1016/j.blre.2015.12.003PubMedPubMed CentralGoogle Scholar
- Naik RP, Streiff MB, Haywood C. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013; 126(5):443-449. https://doi.org/10.1016/j.amjmed.2012.12.016PubMedPubMed CentralGoogle Scholar
- James AH, Jamison MG, Brancazio LR. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006; 194(5):1311-1315. https://doi.org/10.1016/j.ajog.2005.11.008PubMedGoogle Scholar
- Seaman CD, Yabes J, Li J. Venous thromboembolism in pregnant women with sickle cell disease: a retrospective database analysis. Thromb Res. 2014; 134(6):1249-1252. https://doi.org/10.1016/j.thromres.2014.09.037PubMedGoogle Scholar
- Folsom AR, Tang W, Roetker NS. Prospective study of sickle cell trait and venous thromboembolism incidence. J Thromb Haemost. 2015; 13(1):2-9. https://doi.org/10.1111/jth.12787PubMedPubMed CentralGoogle Scholar
- Little I, Vinogradova Y, Orton E. Venous thromboembolism in adults screened for sickle cell trait: a populationbased cohort study with nested case-control analysis. BMJ Open. 2017; 7(3):e012665. https://doi.org/10.1136/bmjopen-2016-012665PubMedPubMed CentralGoogle Scholar
- Ogunsile FJ, Naik R, Lanzkron S. Overcoming challenges of venous thromboembolism in sickle cell disease treatment. Expert Rev Hematol. 2019; 12(3):173-182. https://doi.org/10.1080/17474086.2019.1583554PubMedGoogle Scholar
- Kumar R, Stanek J, Creary S. Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study. Blood Adv. 2018; 2(3):285-291. https://doi.org/10.1182/bloodadvances.2017012336PubMedPubMed CentralGoogle Scholar
- Srisuwananukorn A, Raslan R, Zhang X. Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. Blood Adv. 2020; 4(9):1978-1986. https://doi.org/10.1182/bloodadvances.2019001384PubMedPubMed CentralGoogle Scholar
- Yu TT, Nelson J, Streiff MB. Risk factors for venous thromboembolism in adults with hemoglobin SC or Sbeta(+) thalassemia genotypes. Thromb Res. 2016; 141:35-38. https://doi.org/10.1016/j.thromres.2016.03.003PubMedPubMed CentralGoogle Scholar
- Lettre G, Sankaran VG, Bezerra MA. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A. 2008; 105(33):11869-11874. Google Scholar
- Raffield LM, Ulirsch JC, Naik RP. Common alpha-globin variants modify hematologic and other clinical phenotypes in sickle cell trait and disease. PLoS Genet. 2018; 14(3):e1007293. Google Scholar
- Thein SL, Menzel S, Peng X. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A. 2007; 104(27):11346-11351. https://doi.org/10.1371/journal.pgen.1007293PubMedPubMed CentralGoogle Scholar
- Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood. 2014; 123(12):1794-1801. https://doi.org/10.1073/pnas.0611393104PubMedPubMed CentralGoogle Scholar
- Zakai NA, McClure LA, Judd SE. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation. 2014; 129(14):1502-1509. https://doi.org/10.1182/blood-2013-12-512681PubMedGoogle Scholar
- Zimmerman SA, Ware RE. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol. 1998; 59(4):267-272. https://doi.org/10.1161/CIRCULATIONAHA.113.006472PubMedPubMed CentralGoogle Scholar
- Zimmerman SA, Howard TA, Whorton MR. Thrombophilic DNA mutations as independent risk factors for stroke and avascular necrosis in sickle cell anemia. Hematology. 2001; 6(5):347-353. https://doi.org/10.1002/(SICI)1096-8652(199812)59:4<267::AID-AJH1>3.0.CO;2-WGoogle Scholar
- Heit JA, Armasu SM, McCauley BM. Identification of unique venous thromboembolism- susceptibility variants in African- Americans. Thromb Haemost. 2017; 117(4):758-768. https://doi.org/10.1080/10245332.2001.11746590PubMedGoogle Scholar
- Lin F, Blake DL, Callebaut I. MAN1, an inner nuclear membrane protein that shares the LEM domain with lamina-associated polypeptide 2 and emerin. J Biol Chem. 2000; 275(7):4840-4847. https://doi.org/10.1160/TH16-08-0652PubMedPubMed CentralGoogle Scholar
- Bourgeois B, Gilquin B, Tellier-Lebegue C. Inhibition of TGF-beta signaling at the nuclear envelope: characterization of interactions between MAN1, Smad2 and Smad3, and PPM1A. Sci Signal. 2013; 6(280):ra49. https://doi.org/10.1074/jbc.275.7.4840PubMedGoogle Scholar
- Nagai Y, Shimazu R, Ogata H. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood. 2002; 99(5):1699-1705. https://doi.org/10.1126/scisignal.2003411PubMedPubMed CentralGoogle Scholar
- Ortiz-Suarez ML, Bond PJ. The structural basis for lipid and endotoxin binding in RP105-MD-1, and consequences for regulation of host lipopolysaccharide sensitivity. Structure. 2016; 24(1):200-211. https://doi.org/10.1182/blood.V99.5.1699PubMedGoogle Scholar
- Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost. 2004; 2(4):619-622. https://doi.org/10.1016/j.str.2015.10.021PubMedGoogle Scholar
- Perner F, Perner C, Ernst T. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells. 2019; 8(8):854. https://doi.org/10.1111/j.1538-7836.2004.00689.xPubMedGoogle Scholar
- Shet AS, Wun T. How I diagnose and treat venous thromboembolism in sickle cell disease. Blood. 2018; 132(17):1761-1769. https://doi.org/10.3390/cells8080854PubMedPubMed CentralGoogle Scholar
- Ansari J, Gavins FNE. Ischemia-reperfusion injury in sickle cell disease: from basics to therapeutics. Am J Pathol. 2019; 189(4):706-718. https://doi.org/10.1182/blood-2018-03-822593PubMedPubMed CentralGoogle Scholar
- Sparkenbaugh E, Pawlinski R. Prothrombotic aspects of sickle cell disease. J Thromb Haemost. 2017; 15(7):1307-1316. https://doi.org/10.1016/j.ajpath.2018.12.012PubMedPubMed CentralGoogle Scholar
- Ataga KI, Moore CG, Hillery CA. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008; 93(1):20-26. https://doi.org/10.1111/jth.13717PubMedGoogle Scholar
- Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018; 68(2-3):263-299. https://doi.org/10.3324/haematol.11763PubMedGoogle Scholar
- Hebbel RP. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am. 2014; 28(2):181-198. https://doi.org/10.3233/CH-189012PubMedPubMed CentralGoogle Scholar
- Belcher JD, Chen C, Nguyen J. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014; 123(3):377-390. https://doi.org/10.1016/j.hoc.2013.11.005PubMedGoogle Scholar
- Zhang D, Xu C, Manwani D. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016; 127(7):801-809. https://doi.org/10.1182/blood-2013-04-495887PubMedPubMed CentralGoogle Scholar
- Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019; 14:263-292. https://doi.org/10.1182/blood-2015-09-618538PubMedPubMed CentralGoogle Scholar
- Mendonca R, Silveira AA, Conran N. Red cell DAMPs and inflammation. Inflamm Res. 2016; 65(9):665-678. https://doi.org/10.1146/annurev-pathmechdis-012418-012838PubMedPubMed CentralGoogle Scholar
- Lawson CA, Yan SD, Yan SF. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest. 1997; 99(7):1729-1738. https://doi.org/10.1007/s00011-016-0955-9PubMedGoogle Scholar
- Yan SF, Zou YS, Gao Y. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A. 1998; 95(14):8298-8303. https://doi.org/10.1172/JCI119337PubMedPubMed CentralGoogle Scholar
- Houston P, Dickson MC, Ludbrook V. Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1. Arterioscler Thromb Vasc Biol. 1999; 19(2):281-289. https://doi.org/10.1073/pnas.95.14.8298PubMedPubMed CentralGoogle Scholar
- Solovey A, Gui L, Key NS. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998; 101(9):1899-1904. https://doi.org/10.1161/01.ATV.19.2.281PubMedGoogle Scholar
- Key NS, Slungaard A, Dandelet L. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998; 91(11):4216-4223. https://doi.org/10.1172/JCI1932PubMedPubMed CentralGoogle Scholar
- Shet AS, Aras O, Gupta K. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003; 102(7):2678-2683. https://doi.org/10.1182/blood.V91.11.4216PubMedGoogle Scholar
- Ragab SM, Soliman MA. Tissue factor-positive monocytes expression in children with sickle cell disease: clinical implication and relation to inflammatory and coagulation markers. Blood Coagul Fibrinolysis. 2016; 27(8):862-869. https://doi.org/10.1182/blood-2003-03-0693PubMedGoogle Scholar
- Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol. 2001; 38(1 Suppl 1):14-22. https://doi.org/10.1097/MBC.0000000000000494PubMedGoogle Scholar
- Connes P, Alexy T, Detterich J. The role of blood rheology in sickle cell disease. Blood Rev. 2016; 30(2):111-118. https://doi.org/10.1053/shem.2001.20140Google Scholar
- Colin Y, Le Van Kim C, El Nemer W. Red cell adhesion in human diseases. Curr Opin Hematol. 2014; 21(3):186-192. https://doi.org/10.1016/j.blre.2015.08.005PubMedPubMed CentralGoogle Scholar
- Goel MS, Diamond SL. Adhesion of normal erythrocytes at depressed venous shear rates to activated neutrophils, activated platelets, and fibrin polymerized from plasma. Blood. 2002; 100(10):3797-3803. https://doi.org/10.1097/MOH.0000000000000036PubMedGoogle Scholar
- Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood. 2001; 98(12):3228-3233. https://doi.org/10.1182/blood-2002-03-0712PubMedGoogle Scholar
- van Beers EJ, Schaap MC, Berckmans RJ. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009; 94(11):1513-1519. https://doi.org/10.1182/blood.V98.12.3228PubMedGoogle Scholar
- Aleman MM, Byrnes JR, Wang JG. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest. 2014; 124(8):3590-3600. https://doi.org/10.3324/haematol.2009.008938PubMedPubMed CentralGoogle Scholar
- Byrnes JR, Wolberg AS. Red blood cells in thrombosis. Blood. 2017; 130(16):1795-1799. https://doi.org/10.1172/JCI75386PubMedPubMed CentralGoogle Scholar
- Faes C, Ilich A, Sotiaux A. Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood. 2019; 133(23):2529-2541. https://doi.org/10.1182/blood-2017-03-745349PubMedPubMed CentralGoogle Scholar
- Stein PD, Beemath A, Meyers FA. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med. 2006; 119(10):897. https://doi.org/10.1182/blood.2019000424PubMedPubMed CentralGoogle Scholar
- Adedeji MO, Cespedes J, Allen K. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med. 2001; 125(11):1436-1441. https://doi.org/10.1016/j.amjmed.2006.08.015PubMedGoogle Scholar
- Solovey A, Kollander R, Shet A. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004; 104(3):840-846. Google Scholar
- Vats R, Brzoska T, Bennewitz MF. Platelet extracellular vesicles drive inflammasome- IL-1beta-dependent lung injury in sickle cell disease. Am J Respir Crit Care Med. 2020; 201(1):33-46. https://doi.org/10.1182/blood-2003-10-3719PubMedGoogle Scholar
- Wun T, Paglieroni T, Field CL. Plateleterythrocyte adhesion in sickle cell disease. J Investig Med. 1999; 47(3):121-127. https://doi.org/10.1164/rccm.201807-1370OCPubMedPubMed CentralGoogle Scholar
- Wun T, Cordoba M, Rangaswami A. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol. 2002; 24(2):81-88. Google Scholar
- Polanowska-Grabowska R, Wallace K, Field JJ. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol. 2010; 30(12):2392-2399. https://doi.org/10.1046/j.1365-2257.2002.t01-1-00433.xGoogle Scholar
- Vogel S, Arora T, Wang X. The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase. Blood Adv. 2018; 2(20):2672-2680. https://doi.org/10.1161/ATVBAHA.110.211615PubMedPubMed CentralGoogle Scholar
- Novelli EM, Little-Ihrig L, Knupp HE. Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2019; 316(6):L1150-L1164. https://doi.org/10.1182/bloodadvances.2018021709PubMedPubMed CentralGoogle Scholar
- Garrido VT, Sonzogni L, Mtatiro SN. Association of plasma CD40L with acute chest syndrome in sickle cell anemia. Cytokine. 2017; 97:104-107. https://doi.org/10.1152/ajplung.00302.2018PubMedPubMed CentralGoogle Scholar
- Anea CB, Lyon M, Lee IA. Pulmonary platelet thrombi and vascular pathology in acute chest syndrome in patients with sickle cell disease. Am J Hematol. 2016; 91(2):173-178. https://doi.org/10.1016/j.cyto.2017.05.017PubMedGoogle Scholar
- Allali S, Maciel TT, Hermine O. Innate immune cells, major protagonists of sickle cell disease pathophysiology. Haematologica. 2020; 105(2):273-283. https://doi.org/10.1002/ajh.24224PubMedPubMed CentralGoogle Scholar
- Thalin C, Hisada Y, Lundstrom S. Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis. Arterioscler Thromb Vasc Biol. 2019; 39(9):1724-1738. https://doi.org/10.3324/haematol.2019.229989PubMedPubMed CentralGoogle Scholar
- Noubouossie DF, Whelihan MF, Yu YB. In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood. 2017; 129(8):1021-1029. https://doi.org/10.1161/ATVBAHA.119.312463PubMedPubMed CentralGoogle Scholar
- Ulug P, Vasavda N, Kumar R. Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia. Am J Hematol. 2008; 83(9):714-716. https://doi.org/10.1182/blood-2016-06-722298PubMedPubMed CentralGoogle Scholar
- Chen G, Zhang D, Fuchs TA. Hemeinduced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014; 123(24):3818-3827. Google Scholar
- Ataga KI, Kutlar A, Kanter J. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017; 376(5):429-439. https://doi.org/10.1002/ajh.21237PubMedGoogle Scholar
- Kalra VK, Zhang S, Malik P. Placenta growth factor mediated gene regulation in sickle cell disease. Blood Rev. 2018; 32(1):61-70. https://doi.org/10.1182/blood-2013-10-529982PubMedPubMed CentralGoogle Scholar
- Belcher JD, Marker PH, Weber JP. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000; 96(7):2451-2459. https://doi.org/10.1056/NEJMoa1611770PubMedPubMed CentralGoogle Scholar
- Mackman N. Regulation of the tissue factor gene. Thromb Haemost. 1997; 78(1):747-754. https://doi.org/10.1016/j.blre.2017.08.008PubMedPubMed CentralGoogle Scholar
- Liu Y, Zhong H, Bao W. Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD. Blood. 2019; 134(7):579-590. https://doi.org/10.1182/blood.V96.7.2451PubMedGoogle Scholar
- Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008; 359(9):938-949. https://doi.org/10.1055/s-0038-1657623PubMedGoogle Scholar
- Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018; 38(4):709-725. https://doi.org/10.1182/blood.2019000172PubMedPubMed CentralGoogle Scholar
- Witkowski M, Landmesser U, Rauch U. Tissue factor as a link between inflammation and coagulation. Trends Cardiovasc Med. 2016; 26(4):297-303. https://doi.org/10.1056/NEJMra0801082PubMedGoogle Scholar
- Giesen PL, Rauch U, Bohrmann B. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999; 96(5):2311-2315. https://doi.org/10.1161/ATVBAHA.117.309846PubMedGoogle Scholar
- Solovey A, Somani A, Belcher JD. A monocyte-TNF-endothelial activation axis in sickle transgenic mice: therapeutic benefit from TNF blockade. Am J Hematol. 2017; 92(11):1119-1130. https://doi.org/10.1016/j.tcm.2015.12.001PubMedGoogle Scholar
- Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost. 2001; 86(1):51-56. https://doi.org/10.1073/pnas.96.5.2311PubMedPubMed CentralGoogle Scholar
- Ansari SA, Pendurthi UR, Rao LVM. Role of cell surface lipids and thiol-disulphide exchange pathways in regulating the encryption and decryption of tissue factor. Thromb Haemost. 2019; 119(6):860-870. https://doi.org/10.1002/ajh.24856PubMedPubMed CentralGoogle Scholar
- Arumugam PI, Mullins ES, Shanmukhappa SK. Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood. 2015; 126(15):1844-1855. https://doi.org/10.1055/s-0037-1616200PubMedGoogle Scholar
- Nasimuzzaman M, Malik P. Role of the coagulation system in the pathogenesis of sickle cell disease. Blood Adv. 2019; 3(20):3170-3180. https://doi.org/10.1055/s-0039-1681102PubMedGoogle Scholar
- Leslie J, Langler D, Serjeant GR. Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. Br J Haematol. 1975; 30(2):159-166. https://doi.org/10.1182/blood-2015-01-625707PubMedPubMed CentralGoogle Scholar
- Francis RB. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis. 1991; 2(2):341-353. https://doi.org/10.1182/bloodadvances.2019000193PubMedPubMed CentralGoogle Scholar
- Hagger D, Wolff S, Owen J. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis. 1995; 6(2):93-99. https://doi.org/10.1111/j.1365-2141.1975.tb00530.xPubMedGoogle Scholar
- Noubouossie DF, Lê PQ, Corazza F. Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. Am J Hematol. 2012; 87(2):145-149. https://doi.org/10.1097/00001721-199104000-00018PubMedGoogle Scholar
- Noubouossie DF, Henderson MW, Mooberry M. Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood. 2020; 135(10):755-765. https://doi.org/10.1097/00001721-199504000-00001PubMedGoogle Scholar
- Whelihan MF, Lim MY, Mooberry MJ. Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. J Thromb Haemost. 2016; 14(10):1941-1952. https://doi.org/10.1002/ajh.22206PubMedGoogle Scholar
- Amin C, Adam S, Mooberry MJ. Coagulation activation in sickle cell trait: an exploratory study. Br J Haematol. 2015; 171(4):638-646. https://doi.org/10.1182/blood.2019001643PubMedPubMed CentralGoogle Scholar
- Stark K, Philippi V, Stockhausen S. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood. 2016; 128(20):2435-2449. https://doi.org/10.1111/jth.13416PubMedGoogle Scholar
- Xu H, Wandersee NJ, Guo Y. Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation. Blood. 2014; 124(26):3978-3981. https://doi.org/10.1111/bjh.13641PubMedPubMed CentralGoogle Scholar
- Merle NS, Grunenwald A, Rajaratnam H. Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight. 2018; 3(12):e96910. https://doi.org/10.1182/blood-2016-04-710632PubMedPubMed CentralGoogle Scholar
- Camus SM, De Moraes JA, Bonnin P. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood. 2015; 125(24):3805-3814. https://doi.org/10.1182/blood-2014-04-560813PubMedPubMed CentralGoogle Scholar
- Reiter CD, Wang X, Tanus-Santos JE. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002; 8(12):1383-1389. https://doi.org/10.1172/jci.insight.96910PubMedPubMed CentralGoogle Scholar
- Setty BN, Betal SG, Zhang J. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost. 2008; 6(12):2202-2209. https://doi.org/10.1182/blood-2014-07-589283PubMedPubMed CentralGoogle Scholar
- Merle NS, Paule R, Leon J. P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR- 4/heme-dependent manner. Proc Natl Acad Sci U S A. 2019; 116(13):6280-6285. https://doi.org/10.1038/nm1202-799PubMedGoogle Scholar
- Roumenina LT, Chadebech P, Bodivit G. Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol. 2020; 95(5):456-464. https://doi.org/10.1111/j.1538-7836.2008.03177.xPubMedGoogle Scholar
- Sparkenbaugh EM, Chen C, Brzoska T. Thrombin-mediated activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease. Blood. 2020; 135(20):1783-1787. https://doi.org/10.1073/pnas.1814797116PubMedPubMed CentralGoogle Scholar
- Gilbert GE, Sims PJ, Wiedmer T. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem. 1991; 266(26):17261-17268. https://doi.org/10.1002/ajh.25742PubMedGoogle Scholar
- Hrachovinova I, Cambien B, Hafezi- Moghadam A. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 2003; 9(8):1020-1025. https://doi.org/10.1182/blood.2019003543PubMedPubMed CentralGoogle Scholar
- Gross PL, Furie BC, Merrill-Skoloff G. Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol. 2005; 78(6):1318-1326. Google Scholar
- Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017; 129(20):2719-2726. https://doi.org/10.1038/nm899PubMedGoogle Scholar
- Ranque B, Menet A, Boutouyrie P. Arterial stiffness impairment in sickle cell disease associated with chronic vascular complications: the multinational African CADRE study. Circulation. 2016; 134(13):923-933. https://doi.org/10.1189/jlb.0405193PubMedGoogle Scholar
- Belhassen L, Pelle G, Sediame S. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood. 2001; 97(6):1584-1589. https://doi.org/10.1182/blood-2017-02-765891PubMedPubMed CentralGoogle Scholar
- Powars DR, Chan LS, Hiti A. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005; 84(6):363-376. https://doi.org/10.1161/CIRCULATIONAHA.115.021015PubMedGoogle Scholar
- Mehari A, Gladwin MT, Tian X. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012; 307(12):1254-1256. https://doi.org/10.1182/blood.V97.6.1584PubMedGoogle Scholar
- Kearon C, Akl EA, Ornelas J. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016; 149(2):315-352. https://doi.org/10.1097/01.md.0000189089.45003.52PubMedGoogle Scholar
- Tritschler T, Kraaijpoel N, Le Gal G. Venous thromboembolism: advances in diagnosis and treatment. JAMA. 2018; 320(15):1583-1594. https://doi.org/10.1001/jama.2012.358PubMedPubMed CentralGoogle Scholar
- Liem RI, Lanzkron S, Coates TD. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019; 3(23):3867-3897. https://doi.org/10.1016/j.chest.2015.11.026PubMedGoogle Scholar
- Hariharan N, Brunson A, Mahajan A. Bleeding in patients with sickle cell disease: a population-based study. Blood Adv. 2020; 4(5):793-802. https://doi.org/10.1001/jama.2018.14346PubMedGoogle Scholar
- van Es N, Coppens M, Schulman S. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014; 124(12):1968-1975. https://doi.org/10.1182/bloodadvances.2019000916PubMedPubMed CentralGoogle Scholar
- Li A, Garcia DA, Lyman GH. Direct oral anticoagulant (DOAC) versus low-molecular- weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019; 173:158-163. https://doi.org/10.1182/bloodadvances.2019000940PubMedPubMed CentralGoogle Scholar
- Roberts MZ, Gaskill GE, Kanter-Washko J. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study. J Thromb Thrombolysis. 2018; 45(4):512-515. https://doi.org/10.1182/blood-2014-04-571232PubMedGoogle Scholar
- Patel A, Williams H, Baer MR. Decreased bleeding incidence with direct oral anticoagulants compared to vitamin K antagonist and low-molecular-weight heparin in patients with sickle cell disease and venous thromboembolism. Acta Haematol. 2019; 142(4):233-238. https://doi.org/10.1016/j.thromres.2018.02.144PubMedPubMed CentralGoogle Scholar
- Colella MP, De Paula EV, Conran N. Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. J Thromb Haemost. 2012; 10(9):1967-1970. https://doi.org/10.1007/s11239-018-1637-yPubMedPubMed CentralGoogle Scholar
- Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014; 40(3):348-358. https://doi.org/10.1159/000500223PubMedGoogle Scholar
- Kutlar A, Kanter J, Liles DK. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol. 2019; 94(1):55-61. https://doi.org/10.1111/j.1538-7836.2012.04861.xPubMedGoogle Scholar
- Heeney MM, Hoppe CC, Abboud MR. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016; 374(7):625-635. https://doi.org/10.1055/s-0034-1370794PubMedGoogle Scholar
- Weitz JI, Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism. Blood. 2020; 135(5):351-359. https://doi.org/10.1002/ajh.25308PubMedGoogle Scholar
- Buller HR, Bethune C, Bhanot S. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015; 372(3):232-240. Google Scholar
- Brighton TA, Eikelboom JW, Mann K. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012; 367(21):1979-1987. https://doi.org/10.1056/NEJMoa1512021PubMedGoogle Scholar
- Glynn RJ, Danielson E, Fonseca FA. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009; 360(18):1851-1861. https://doi.org/10.1182/blood.2019000919PubMedGoogle Scholar
- Hoppe C, Jacob E, Styles L. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol. 2017; 177(4):620-629. https://doi.org/10.1056/NEJMoa1405760PubMedPubMed CentralGoogle Scholar
- Ridker PM, Everett BM, Thuren T. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377(12):1119-1131. https://doi.org/10.1056/NEJMoa1210384PubMedGoogle Scholar
- Austin H, Key NS, Benson JM. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood. 2007; 110(3):908-912. https://doi.org/10.1056/NEJMoa0900241PubMedPubMed CentralGoogle Scholar
Data Supplements
Figures & Tables
Article Information
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.